All In Biotech

NDA 021485 · Orion Pharma

Stalevo 75

Carbidopa, Entacapone, Levodopa · Oral · Aromatic Amino Acid Decarboxylation Inhibitor; Catechol-O-Methyltransferase Inhibitor; Aromatic Amino Acid

Last checked: Nov 20, 2026Latest source record: Mar 19, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2003

Jun 11, 2003

Approved uses

1

Original approval plus efficacy supplements

Registered trials

262

53 Phase 3, 16 recruiting

FAERS reports

481

355 serious, 88 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 19, 2026.

Carbidopa, levodopa and entacapone tablets are indicated for the treatment of Parkinson's disease. Carbidopa, levodopa and entacapone tablets can be used: • To substitute (with equivalent strengths of each of the three components) carbidopa/levodopa and entacapone previously administered as individual products. • To replace carbidopa/levodopa therapy (without entacapone) when patients experience the signs and symptoms of end-of-dose “wearing-off” and when they have been taking a total daily dose of levodopa of 600 mg or less and have not been experiencing dyskinesias. Carbidopa, levodopa and entacapone tablets, a combination drug consisting of levodopa (aromatic amino acid), carbidopa (aromatic amino acid decarboxylation inhibitor), and entacapone (catechol-O-methyltransferase (COMT) inhibitor) is indicated for the treatment of Parkinson's disease. Carbidopa, levodopa and entacapone tablets is to be used: • To substitute (with equivalent strengths of each of the three components) for carbidopa/levodopa and entacapone previously administered as individual products ( 1 ) • To replace carbidopa/levodopa therapy (without entacapone) when patients experience the signs and symptoms of end-of-dose “wearing-off” and when they have been taking a total daily dose of levodopa of 600 mg or less and have not been experiencing dyskinesias ( 1 )

Mechanism: Levodopa Current evidence indicates that symptoms of Parkinson's disease are related to depletion of dopamine in the corpus striatum. Administration of dopamine is ineffective in the treatment of Parkinson's disease because it does not cross the blood-brain barrier. However, levodopa the metabolic precursor of dopamine, does cross the blood-brain barrier, and is presumably converted to dopamine in the brain. This is thought to be the mechanism whereby levodopa relieves the symptoms of Parkinson's disease. Carbidopa When levodopa is administered orally, it is rapidly decarboxylated to dopamine...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

6 products under this application
  • STALEVO 75 · CARBIDOPA 18.75MG; ENTACAPONE 200MG; LEVODOPA 75MG · TABLET, ORAL · Prescription · TE AB
  • STALEVO 150 · CARBIDOPA 37.5MG; ENTACAPONE 200MG; LEVODOPA 150MG · TABLET, ORAL · Prescription · TE AB
  • STALEVO 50 · CARBIDOPA 12.5MG; ENTACAPONE 200MG; LEVODOPA 50MG · TABLET, ORAL · Prescription · TE AB
  • STALEVO 125 · CARBIDOPA 31.25MG; ENTACAPONE 200MG; LEVODOPA 125MG · TABLET, ORAL · Prescription · TE AB
  • STALEVO 200 · CARBIDOPA 50MG; ENTACAPONE 200MG; LEVODOPA 200MG · TABLET, ORAL · Prescription · TE AB
  • STALEVO 100 · CARBIDOPA 25MG; ENTACAPONE 200MG; LEVODOPA 100MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Carbidopa" as an intervention, any sponsor and status, largest first.

All 262 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fall69
  • death54
  • hallucination52
  • drug ineffective43
  • parkinson^s disease41
  • dyskinesia27
  • urinary tract infection27
  • product dose omission issue25
  • confusional state24
  • device issue21
  • fatigue18
  • somnolence18

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20113
20121
20133
20144
20153
20169
201734
201842
201938
202061
202157
202264
202360
202446
202556

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Stalevo 100 (Carbidopa/Levodopa/Entacapone)

2024 spending

$130K

Beneficiaries

16

93 claims

Per beneficiary

$8,126

$7.25 per unit

View as table
YearSpending
2020$15,438
2021$368,257
2022$332,847
2023$228,542
2024$130,010

Part D: Stalevo 150 (Carbidopa/Levodopa/Entacapone)

2024 spending

$40K

Beneficiaries

11

41 claims

Per beneficiary

$3,613

$7.58 per unit

View as table
YearSpending
2020$0
2021$89,994
2022$207,419
2023$127,388
2024$39,744

Part D: Stalevo 200 (Carbidopa/Levodopa/Entacapone)

2024 spending

$41K

Beneficiaries

12

41 claims

Per beneficiary

$3,418

$6.66 per unit

View as table
YearSpending
2020$0
2021$140,274
2022$328,110
2023$151,379
2024$41,016

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 545 on PubMed

Sponsor: Orion Pharma · Also marketed as Stalevo 150, Stalevo 50, Stalevo 125, Stalevo 200, Stalevo 100

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.